Table 6.
PRO questionnaires use in Phase 2 and Phase 3 trials.
| PRO QUESTIONNAIRE | PHASE 2 TRIALS USING PRO (n = 14) n (%)* | PHASE 3 TRIALS USING PRO (n = 24) n (%)* |
|---|---|---|
| FACT-B | 7 (50.0%) | 11 (45.8%) |
| EORTC QLQ-C30 | 4 (28.6%) | 10 (41.7%) |
| EQ-5D | 3 (21.4%) | 5 (20.8%) |
| EORTC QLQ-BR23 | 1 (7.1%) | 4 (16.7%) |
| BPI | 2 (14.3%) | 1 (4.2%) |
| FACT-G | – | 3 (12.5%) |
| MDASI | 1 (7.1%) | 1 (4.2%) |
| HADS | – | 2 (8.3%) |
| RSCL | – | 2 (8.3%) |
| EQ-5D-5L | – | 2 (8.3%) |
| FACIT-F | – | 1 (4.2%) |
| FACT-ES | – | 1 (4.2%) |
| MAF | 1 (7.1%) | – |
| PSQI | – | 1 (4.2%) |
| SF-36 | – | 1 (4.2%) |
| SPHERE | – | 1 (4.2%) |
| SSQ | – | 1 (4.2%) |
Note:
*
Counts not mutually exclusive.